[HTML][HTML] The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study
Objective We aimed to describe sociodemographic, comorbidities, co-medication and risk of
thromboembolic events and bleeding in patients with NVAF initiating oral anticoagulants …
thromboembolic events and bleeding in patients with NVAF initiating oral anticoagulants …
[HTML][HTML] Efectividad, seguridad y costes de la prevención tromboembólica en fibrilación auricular. Estudio de cohortes apareado por Propensity score
M Giner-Soriano, M Casajuana, A Roso-Llorach… - Atención Primaria, 2020 - Elsevier
Objetivo El objetivo de este estudio es analizar el uso, la efectividad, la seguridad y los
costes de la prevención de ictus en fibrilación auricular (FA) no valvular en pacientes que …
costes de la prevención de ictus en fibrilación auricular (FA) no valvular en pacientes que …
The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the …
M van Hulst, J Stevanovic, MS Jacobs… - Journal of Medical …, 2018 - Taylor & Francis
Background: Atrial fibrillation (AF) causes a significant health and economic burden to the
Dutch society. Dabigatran was proven to have at least similar efficacy and a similar or better …
Dutch society. Dabigatran was proven to have at least similar efficacy and a similar or better …
[HTML][HTML] Incidence and cost of bleeding events requiring hospitalization in patients with atrial fibrillation treated with acenocoumarol in Greece
G Kourlaba, G Stefanou, S Tsalamandris… - Hellenic Journal of …, 2021 - Elsevier
Background To estimate the incidence of hemorrhagic events in patients with atrial
fibrillation (AF) treated with acenocoumarol, and the management cost of those requiring …
fibrillation (AF) treated with acenocoumarol, and the management cost of those requiring …
Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
A De Veer, N Bennaghmouch, M Wijffels… - Netherlands Heart …, 2019 - Springer
Background Current guidelines recommend non-vitamin‑K oral anticoagulants (NOACs) as
the first-choice therapy for stroke prevention in patients with atrial fibrillation (AF). The use of …
the first-choice therapy for stroke prevention in patients with atrial fibrillation (AF). The use of …
Role of hypertension and other clinical variables in prognostication of patients presenting to the emergency department with major bleeding events
A Conti, D Molesti, S Bianchi, S Catarzi… - Critical Pathways in …, 2018 - journals.lww.com
Background: Clinical variables including hypertension could be linked with major bleeding
events and death beyond vitamin K antagonist (warfarin) or direct oral anti-coagulants …
events and death beyond vitamin K antagonist (warfarin) or direct oral anti-coagulants …
Predicción de tiempo en rango terapéutico para pacientes con fibrilación auricular no valvular (FANV) anticoagulados con antivitamina k (AVK)
L Pérez Orero - 2023 - riunet.upv.es
[ES] Introducción: La fibrilación auricular (FA) es la arritmia cardiaca más frecuente y está
relacionada con eventos embólicos. La eficacia y seguridad de la anticoagulación con …
relacionada con eventos embólicos. La eficacia y seguridad de la anticoagulación con …
CHADS2 risk score and rate of stroke or systemic embolism and major bleeding in patients with non-valvular atrial fibrillation receiving non-vitamin K antagonist oral …
W Van Mieghem, P Lancellotti - Acta Cardiologica, 2017 - Taylor & Francis
Randomized trials showed non-inferior or superior results of the non-vitamin K antagonist
oral anticoagulants (NOACs) compared with warfarin in patients with non-valvular atrial …
oral anticoagulants (NOACs) compared with warfarin in patients with non-valvular atrial …
A single institution's experience with using dabigatran, rivaroxaban and warfarin for prevention of thromboembolism in atrial fibrillation
LX Chan, YM Wong, PL Chia… - … of Singapore Healthcare, 2018 - journals.sagepub.com
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are approved
for stroke prevention in atrial fibrillation (AF) patients, their use in the local clinical setting has …
for stroke prevention in atrial fibrillation (AF) patients, their use in the local clinical setting has …
Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants
AS Moss, G Dimitropoulous, GYH Lip - Expert Review of …, 2017 - Taylor & Francis
Introduction: The use of non-Vitamin K antagonist oral anticoagulant (NOAC) drugs is
increasingly common in clinical practice. As compared to vitamin K antagonists they are …
increasingly common in clinical practice. As compared to vitamin K antagonists they are …